



Once you have made the clinical decision to prescribe a Johnson & Johnson medicine, support is available

J&J withMe

Helping you support your patients living with cancer

J&J withMe is your single source for access, affordability, and treatment support programs from Johnson & Johnson.

 **DARZALEX**[®]
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro**[®]
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000 units

 **TECVAYLI**[®]
(teclistamab-cqyv) injection for
subcutaneous use
10 mg/mL and 90 mg/mL

 **TALVEY**[®]
(talquetamab-tgvs) injection for
subcutaneous use
2 mg/mL and 40 mg/mL

 **Akeega**[®]
(niraparib/abiraterone acetate)
100mg/500mg tablets • 50mg/500mg tablets

 **Erleada**[®]
(apalutamide) 60mg tablets
240mg tablet

 **inlexzo**[™]
gemcitabine intravesical
system | 225 mg

 **RYBREVENT**[®]
(amivantamab-vmjw)
Injection for IV Use | 350 mg/7 mL (50 mg/mL)

 **LAZCLUZE**[®]
(lazertinib)
Tablets | 240 mg/80 mg

Please read full Prescribing Information for **DARZALEX**[®], **DARZALEX FASPRO**[®], **AKEEGA**[®], **ERLEADA**[®], **RYBREVENT**[®], **LAZCLUZE**[®], and **INLEXZO**[™] also available at [JNJwithMe.com](https://www.jnjwithme.com). Please read full Prescribing Information, including Boxed Warning, and Medication Guides for **TECVAYLI**[®] and **TALVEY**[®], also available at [JNJwithMe.com](https://www.jnjwithme.com). Provide the appropriate Medication Guide to your patients and encourage discussion.

Johnson & Johnson



We can help make it simple for you to help your patients



For Your Office

J&J withMe provides your office with educational support to help patients throughout their treatment journey.

Access and Affordability Support:

- Benefits investigation support
- Prior authorization support and status monitoring
- Information on the exceptions and appeals process
- Coding and billing information
- Finding cost support options for eligible patients

Dedicated Support From a Field Reimbursement Manager:

- Access, fulfillment, and reimbursement education
- Information on cost support options for eligible patients
- Ability to connect with a specialty pharmacy in case of fulfillment issues



For Your Patients

Your patients will be connected with the program that aligns with their prescribed medicine from J&J. Support includes:



Cost support, including J&J withMe Savings Program and other resources



Free, dedicated 1-on-1 Care Navigator Support



Resources and community connections


For patient cost support enrollment for BALVERSA® (erdafitinib), visit Portal.JNJwithMe.com/express.

Please read full Prescribing Information for [BALVERSA®](#).

J&J withMe

Click Below to Discover Patient Access and Affordability Options

MULTIPLE MYELOMA

 **DARZALEX[®]**
(daratumumab)
Injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro[®]**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

 **TECVAYLI[®]**
(teclistamab-cqyv) Injection for
subcutaneous use
10 mg/mL and 90 mg/mL

 **TALVEY[®]**
(talquetamab-tgvs) Injection for
subcutaneous use
2 mg/mL and 40 mg/mL

PROSTATE

 **Akeega[®]**
(niraparib/abiraterone acetate)
100mg/500mg tablets • 50mg/500mg tablets

 **Erleada[®]**
(apalutamide) 50mg tablets
240 mg tablet

BLADDER

 **inlexzo[™]**
gemcitabine intravesical
system | 225 mg

LUNG

 **RYBREVANT[®]**
(amivantamab-vmjw)
Injection for IV Use | 350 mg/7 mL (50 mg/mL)

 **LAZCLUZE[®]**
(lazertinib)
Tablets | 240 mg/80 mg

Get started with J&J withMe:



[Visit Portal.JNJwithMe.com](https://portal.jnjwithme.com)

to investigate insurance coverage for your patients, enroll your patients in savings, or sign them up for Care Navigator support. Easy access to key support needs in **Provider Express** without an account, password, or Business Associate Agreement (BAA).



[Visit JNJwithMe.com/hcp/](https://www.jnjwithme.com/hcp/)

for access and affordability information for the J&J medicine you prescribed.

Bookmark these links for quick and easy access!



Call

833-JNJ-wMe1 (833-565-9631)

Monday through Friday, 8:00 AM to 8:00 PM ET

Please read full Prescribing Information for **DARZALEX[®]**, **DARZALEX FASPRO[®]**, **AKEEGA[®]**, **ERLEADA[®]**, **RYBREVANT[®]**, **LAZCLUZE[®]**, and **INLEXZO[™]** also available at [JNJwithMe.com](https://www.jnjwithme.com). Please read full Prescribing Information, including Boxed Warning, and Medication Guides for **TECVAYLI[®]** and **TALVEY[®]**, also available at [JNJwithMe.com](https://www.jnjwithme.com). Provide the appropriate Medication Guide to your patients and encourage discussion.

J&J withMe

Get started:



Visit

Portal.JNJwithMe.com



Call

833-JNJ-wMe1 (833-565-9631)

Monday through Friday

8:00 AM to 8:00 PM ET

OR



Visit

JNJwithMe.com/hcp/

**Here's what patients think of the support provided by the
J&J withMe Care Navigators:**

**98% of patients responded they were
comfortable and prepared to start and continue
treatment due to Care Navigator support.***



*Data on file. Johnson & Johnson Health Care Systems Inc. Findings through September 2023 (N=221).

The patient support and resources provided by J&J withMe are not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe a J&J medicine.

© Johnson & Johnson and its affiliates 2025 09/25 cp-489775v2

Johnson & Johnson